SAN FRANCISCO —January 9, 2015—Invitae Corporation announced today that it has filed a registration statement on Form S‐1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Invitae intends to apply to list its common stock on The New York Stock Exchange under the symbol “NVTA.”
J.P. Morgan …
Estimate your out-of-pocket cost for Invitae tests related to a personal or family history of breast, ovarian, colorectal, or uterine cancer.
The amount shown above is an estimate of your out-of-pocket cost based upon the information you entered about your health insurance coverage. It is not a confirmation that the test has been authorized by your insurance provider. Your final cost may vary based upon your health plan design, deductible, co-insurance, and out-of-pocket limits. Learn More >
As part of Invitae’s dedication to making high-quality genetic testing affordable and accessible, we also offer a patient pre-pay option of $250. Learn More >
We could not determine an out-of-pocket estimate. Please contact us for assistance.